ReviewNature reviews. Urology2026
The role of CFTR in spermatogenesis and sperm quality.
Review in Nature reviews. Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic fibrosis (CF) is primarily recognized for its severe systemic effects, especially in the lungs, pancreas and digestive tract. Thus, the effect of CF transmembrane conductance regulator (CFTR) dysfunction on male fertility has been relatively overlooked despite its important roles in spermatogenesis orchestration and spermatozoa function. CFTR has physiological functions as a chloride and bicarbonate channel and a role in regulating water movement. CFTR participates in spermatogenesis, and evidence suggests its involvement in seminiferous intratubular fluid control, maintenance of the blood-testis barrier, and improvement in follicle-stimulating hormone signalling, among other functions. Emerging evidence also suggests that CFTR variant carriers, typically considered to be healthy, have reduced sperm quality. Diminished CFTR expression has been observed in spermatozoa from men with various sperm quality abnormalities (teratozoospermia, asthenozoospermia and oligozoospermia), and correlates positively with sperm motility and morphology. CFTR is thought to be involved in sperm capacitation and osmoregulation via interactions with ion and water channels. Advances in CF therapy, such as CFTR modulators, gene therapy and liposome-mediated CFTR delivery, might affect CFTR's role in sperm function and could potentially be applied to improve the fertility of individuals with CFTR dysfunction.
Identifiers
42362757What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.